Chemexpress(SH:688131) Xin Lang Cai Jing·2025-09-30 03:43Group 1 - The core viewpoint of the news is that Haoyuan Pharmaceutical has seen a stock price increase of 5.07% as of September 30, reaching 81.60 CNY per share, with a total market capitalization of 17.307 billion CNY [1] - Haoyuan Pharmaceutical, established on September 30, 2006, specializes in the research and development of molecular building blocks and tool compounds in the small molecule drug discovery field, as well as the process development and production technology improvement of active pharmaceutical ingredients (APIs) and intermediates [1] - The company's main business revenue composition includes molecular building blocks, tool compounds, and biochemical reagents at 68.97%, with product sales contributing 63.42%, APIs and intermediates at 30.46%, technical services at 5.55%, and other sources at 0.57% [1] Group 2 - From the perspective of fund holdings, Haoyuan Pharmaceutical is a top ten holding of the Hengsheng Qianhai Fund, specifically in the Hengsheng Qianhai Hong Kong-Shenzhen Emerging Industry Selected Mixed Fund (004332), which held 24,600 shares, accounting for 2.1% of the fund's net value [2] - The fund has achieved a year-to-date return of 39.78%, ranking 2105 out of 8167 in its category, and a one-year return of 45.37%, ranking 2370 out of 8010 [2] Group 3 - The fund manager of Hengsheng Qianhai Hong Kong-Shenzhen Emerging Industry Selected Mixed Fund (004332) is Xing Cheng, who has been in the position for 3 years and 193 days, with the fund's total asset size at 252 million CNY [3] - During Xing Cheng's tenure, the best fund return was 87.69%, while the worst return was -29.15% [3]